

# The use of artificial intelligence and mobile health technologies to identify patients at the highest risk of atrial fibrillation (irregular and often abnormally fast heart rate)

<b>Submission date</b> 02/11/2021	<b>Recruitment status</b> Suspended	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 22/11/2021	<b>Overall study status</b> Suspended	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 13/04/2022	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Atrial fibrillation (AF) is the most common heart rhythm disturbance (an irregular and often abnormally fast heart rate). Individuals with atrial fibrillation have an increased risk of developing strokes. AF can be persistent or paroxysmal (intermittent). People with AF can be unaware that they have the condition as they may not display any symptoms. If AF is identified earlier, strokes can be prevented with treatment in the form of a blood thinner (known as anticoagulation). In order to make a diagnosis, a heart tracing called an electrocardiogram (ECG) will be required.

Currently, over 100 individuals will need to be screened in order to pick one individual with AF. However, with our AF risk prediction machine learning algorithm, we predict that we can increase our yield in identifying patients at risk of developing atrial fibrillation. The AF risk prediction machine learning algorithm was developed from previous AF risk score models and primary care data. Early data has suggested that it reduces the number needed to screen to nine to pick one patient with atrial fibrillation.

There has been a recent surge in the number of technologies available for heart rhythm monitoring. As more people have smartphones, this provides us with more opportunities to monitor patients for longer and more frequently and ultimately, diagnose AF earlier. We would like to compare these technologies for AF detection among individuals identified as being at risk of atrial fibrillation by the AF risk prediction machine learning algorithm.

### Aims:

1. To evaluate the potential benefit of using our machine learning algorithm to aid AF screening.
2. To compare the use of different health technologies for AF screening
3. To evaluate the optimal duration and frequency of rhythm monitoring for AF screening

### Who can participate?

Participants who have been identified to be at risk of atrial fibrillation by the AF risk prediction machine learning algorithm. This algorithm will be run on general practice databases in the Hounslow primary care networks to generate a list of potential participants. They must not have a diagnosis of AF already and they must not have a cardiac electronic implantable device to be eligible to participate in the study.

### What does the study involve?

The study involves screening the above participants for AF. All participants will have a single lead ECG using an AliveCor device with a Kardia App. If no AF is identified, the participants will undergo further monitoring for a period of 3 months. The participants will be divided into four groups by cluster randomisation of the general practices. The groups are as follows:

#### 1. ECG group

This group will not have further monitoring after their single lead ECG.

#### 2. Photoplethysmography group

This group will receive a Fibrichk App for their smartphones. They will need to take photoplethysmography recordings with their smartphone twice daily for 3 months. The recordings will be reviewed for the detection of atrial fibrillation.

#### 3. AliveCor group

This group will receive an AliveCor device and a Kardia App for their smartphones. They will need to take single lead ECG recordings with their smartphone twice daily for 3 months. The recordings will be reviewed for the detection of atrial fibrillation.

#### 4. Holter monitoring group

This group will receive 3 Holter monitors/ ECG patches over 3 months. The first monitor will be worn for 72 h. The subsequent monitors will be 24 h. There will be a 6-week interval between monitors.

If AF is identified at any point, the participant will be referred to their clinical team for appropriate treatment.

### What are the possible benefits and risks of participating?

The possible benefits of participating are earlier identification of atrial fibrillation and earlier treatment for atrial fibrillation and therefore possible prevention of further AF related strokes or conditions. However, it is also possible there will be no direct benefit to the research participant. There are no foreseeable risks of participating in this study.

### Where is the study run from?

West Middlesex University Hospital (UK)  
Hounslow Clinical Commissioning Groups

### When is the study starting and how long is it expected to run for?

May 2020 to June 2023

### Who is funding the study?

Bristol Myers Squibb Pharmaceutical Limited (UK)  
Chelsea and Westminster plus charity (UK)

### Who is the main contact?

Dr Pavidra Sivanandarajah (Pavidra.sivanandarajah1@nhs.net)

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Pavidra Sivanandarajah

**ORCID ID**  
<https://orcid.org/0000-0002-6108-4450>

**Contact details**  
Cardiology Department  
West Middlesex University Hospital  
Chelsea and Westminster NHS Foundation Trust  
Twickenham Road  
Isleworth  
London  
United Kingdom  
TW7 6AF  
+44 (0)2083215336  
[pavidra.sivanandarajah1@nhs.net](mailto:pavidra.sivanandarajah1@nhs.net)

## Additional identifiers

**Clinical Trials Information System (CTIS)**  
Nil known

**Integrated Research Application System (IRAS)**  
293493

**ClinicalTrials.gov (NCT)**  
Nil known

**Protocol serial number**  
IRAS 293493, CPMS 50698

## Study information

**Scientific Title**  
Application of machine learning algorithm to identify patients at highest risk of atrial fibrillation for targeted screening

**Acronym**  
AMLA-AF

**Study objectives**  
Current hypothesis as of 29/11/2021:  
The AF risk prediction machine learning algorithm can be used to identify patients at the highest risk of atrial fibrillation (AF) for targeted screening.

---

Previous hypothesis:

The PULsE AI machine learning algorithm can be used to identify patients at the highest risk of atrial fibrillation (AF) for targeted screening

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Approved 01/12/2021, London- Bloomsbury Research Ethics Committee (HRA RES Centre Manchester, 3rd Floor Barlow House, 4 Minshull Street, Manchester M1 3DZ, UK; +44 0207 104 8196; bloomsbury.rec@hra.nhs.uk), ref: 21/LO/0709

### **Study design**

Prospective observational cohort study

### **Primary study design**

Observational

### **Study type(s)**

Screening

### **Health condition(s) or problem(s) studied**

Atrial fibrillation (AF)

### **Interventions**

Current intervention as of 29/11/2021:

Participants will be identified using the AF risk prediction machine learning algorithm from the Hounslow primary care networks.

The study involves screening the above participants for AF. All participants will have a single lead ECG using an AliveCor device with a Kardia App. If no AF is identified, the participants will undergo further monitoring for a period of 3 months. The participants will be divided into four groups by cluster randomisation of the general practices. The groups are as follows:

#### **1. ECG group**

This group will not have further monitoring after their single lead ECG.

#### **2. Photoplethysmography group**

This group will receive a Fibrichk App for their smartphones. They will need to take photoplethysmography recordings with their smartphone twice daily for 3 months. The recordings will be reviewed for the detection of atrial fibrillation.

#### **3. AliveCor group**

This group will receive an AliveCor device and a Kardia App for their smartphones. They will need to take single lead ECG recordings with their smartphone twice daily for 3 months. The recordings will be reviewed for the detection of atrial fibrillation.

#### 4. Holter monitoring group

This group will receive 3 Holter monitors/ ECG patches over 3 months. The first monitor will be worn for 72 h. The subsequent monitors will be 24 h. There will be a 6-week interval between monitors.

If AF is identified at any point, the participant will be referred to their clinical team for appropriate treatment.

---

#### Previous intervention:

Participants will be identified using the PULsE AI machine learning algorithm from the Hounslow primary care networks.

The study involves screening the above participants for AF. All participants will have a single lead ECG using an AliveCor device with a Kardia App. If no AF is identified, the participants will undergo further monitoring for a period of 3 months. The participants will be divided into four groups by cluster randomisation of the general practices. The groups are as follows:

##### 1) ECG group

This group will not have further monitoring after their single lead ECG.

##### 2) Photoplethysmography group

This group will receive a Fibrichk App for their smartphones. They will need to take photoplethysmography recordings with their smartphone twice daily for 3 months. The recordings will be reviewed for the detection of atrial fibrillation.

##### 3) AliveCor group

This group will receive an AliveCor device and a Kardia App for their smartphones. They will need to take single lead ECG recordings with their smartphone twice daily for 3 months. The recordings will be reviewed for the detection of atrial fibrillation.

##### 4) Holter monitoring group

This group will receive 3 Holter monitors/ ECG patches over 3 months. The first monitor will be worn for 72 hrs. The subsequent monitors will be 24hours. There will be a 6-week interval between monitors.

If AF is identified at any point, the participant will be referred to their clinical team for appropriate treatment.

#### **Intervention Type**

Device

#### **Phase**

Not Applicable

#### **Drug/device/biological/vaccine name(s)**

Not applicable

#### **Primary outcome(s)**

Detection of atrial fibrillation with a one-off ECG

**Key secondary outcome(s)**

There are no secondary outcome measures

**Completion date**

30/06/2023

## Eligibility

**Key inclusion criteria**

Current inclusion criteria as of 29/11/2021:

1. Aged 18 years or above
  2. Identified as high-risk for AF by our 'AF risk prediction machine learning algorithm
  3. Access to smartphone depending on allocated screening group
- 

Previous inclusion criteria:

1. Aged 18 years old or above
2. Identified as high-risk for AF by our PULsE AI machine learning algorithm
3. Access to smartphone depending on allocated screening group

**Participant type(s)**

All

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Key exclusion criteria**

1. Have already a diagnosis of atrial fibrillation prior to study enrolment
2. Below the age of 18 years old
3. Presence of cardiac electronic implantable device

**Date of first enrolment**

11/04/2022

**Date of final enrolment**

30/11/2022

## Locations

**Countries of recruitment**

United Kingdom

England

**Study participating centre**

**West Middlesex University Hospital**

Chelsea and Westminster NHS Foundation Trust

Twickenham Road

Isleworth

London

United Kingdom

TW7 6AF

## Sponsor information

**Organisation**

Chelsea and Westminster Hospital NHS Foundation Trust

**ROR**

<https://ror.org/02gd18467>

## Funder(s)

**Funder type**

Industry

**Funder Name**

Bristol-Myers Squibb

**Alternative Name(s)**

Bristol-Myers Squibb Company, Bristol Myers Squibb, Bristol-Myers Company, BMS

**Funding Body Type**

Government organisation

**Funding Body Subtype**

For-profit companies (industry)

**Location**

United States of America

## Funder Name

Chelsea and Westminster plus charity

# Results and Publications

## Individual participant data (IPD) sharing plan

All data generated or analysed during this study will be included in the subsequent results publication

## IPD sharing plan summary

Published as a supplement to the results publication

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">HRA research summary</a>			28/06/2023	No	No
<a href="#">Participant information sheet</a>	Alivecor group version 1.1	25/10/2021	16/11/2021	No	Yes
<a href="#">Participant information sheet</a>	ECG group version 1.0	26/10/2021	16/11/2021	No	Yes
<a href="#">Participant information sheet</a>	Fibricheck group version 1.2	25/10/2021	16/11/2021	No	Yes
<a href="#">Participant information sheet</a>	Holter group version 1.1	25/10/2021	16/11/2021	No	Yes
<a href="#">Participant information sheet</a>	Participant information sheet version 1.1	11/11/2025	11/11/2025	No	Yes
<a href="#">Protocol file</a>		25/10/2021	16/11/2021	No	No